NL129025C
(pm)
*
|
1965-04-29 |
|
|
|
US3542729A
(en)
*
|
1968-03-19 |
1970-11-24 |
Sankyo Co |
Stabilization of synthetic polymers
|
BE790675A
(fr)
*
|
1971-10-29 |
1973-04-27 |
Science Union & Cie |
Nouveaux derives de l'oxa-1 diaza-3,8 spiro (4,5) decane
|
US4244961A
(en)
*
|
1978-10-26 |
1981-01-13 |
Syntex (U.S.A.) Inc. |
1-Oxa-3,8-diazaspiro[4.5]decan-2-ones antihypertensive agents
|
US4255432A
(en)
*
|
1979-09-06 |
1981-03-10 |
Syntex (U.S.A.) Inc. |
8-[2-3-Indolyl)ethyl]-1-oxa-3-,8-diazaspiro[4.5]decan-2-ones, pharmaceutical compositions thereof and methods of use thereof
|
ES517622A0
(es)
*
|
1982-11-23 |
1983-12-16 |
Faes |
Procedimiento de preparacion de un nuevo espirodecano.
|
YU150489A
(sh)
*
|
1989-08-10 |
1992-12-21 |
W.L. Gore & Co. Gmbh. |
Uređaj za ispitivanje odevnih predmeta na nepromočivost
|
HU204054B
(en)
*
|
1989-08-10 |
1991-11-28 |
Richter Gedeon Vegyeszet |
Process for producing new 1-oxa-2-oxo-8-azaspiro(4,5)decane derivatives and pharmaceutical compositions comprising same
|
FR2666583B1
(fr)
*
|
1990-09-06 |
1994-09-09 |
Adir |
Nouveaux derives du spiro [4.5] decane, leur procede de preparation et leurs compositions pharmaceutiques les renfermant.
|
FR2734265B1
(fr)
*
|
1995-05-17 |
1997-06-13 |
Adir |
Nouveaux composes spiro heterocycliques, leur procede de preparation et les compositions pharmaceutiques les contenant
|
US6982251B2
(en)
*
|
2000-12-20 |
2006-01-03 |
Schering Corporation |
Substituted 2-azetidinones useful as hypocholesterolemic agents
|
PT1385548E
(pt)
*
|
2001-01-26 |
2007-08-24 |
Schering Corp |
Combinações de um inibidor ou de inibidores de absorção de esteróis com agente (s) para o tratamento de doenças vasculares
|
US7071181B2
(en)
*
|
2001-01-26 |
2006-07-04 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
|
CA2434488A1
(en)
*
|
2001-01-26 |
2002-08-01 |
Harry R. Davis |
Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
|
SK287746B6
(sk)
*
|
2001-01-26 |
2011-08-04 |
Schering Corporation |
Použitie substituovaných azetidinónových zlúčenín na liečenie sitosterolémie
|
JP2004521894A
(ja)
*
|
2001-01-26 |
2004-07-22 |
シェーリング コーポレイション |
胆汁酸金属イオン封鎖剤およびステロール吸収阻害剤の併用および血管適応症の治療
|
SI1353694T1
(sl)
*
|
2001-01-26 |
2008-06-30 |
Schering Corp |
Kombinacije ezetimiba z aspirinom za zdravljenejevaskularnih stanj
|
PT1353696E
(pt)
*
|
2001-01-26 |
2007-02-28 |
Schering Corp |
Combinações de activador (es) do receptor activado por proliferador do peroxisoma (ppar) e inibidor (es) da absorção de esterol e tratamentos para indicações vasculares
|
EP1392287B8
(en)
*
|
2001-05-25 |
2007-01-10 |
Schering Corporation |
Use of substituted azetidinone derivatives in the treatment of Alzheimer's disease
|
DE10130020A1
(de)
*
|
2001-06-25 |
2003-12-04 |
Gruenenthal Gmbh |
Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate
|
DE10146275A1
(de)
|
2001-09-18 |
2003-04-24 |
Gruenenthal Gmbh |
Kombination ausgewählter Opioide mit Muscarin-Antagonisten zur Therapie der Harninkontinenz
|
ATE345793T1
(de)
*
|
2001-09-21 |
2006-12-15 |
Schering Corp |
Behandlung von xanthom mittels azetidinon- derivate als hemmer der sterol absorption
|
US20030119808A1
(en)
*
|
2001-09-21 |
2003-06-26 |
Schering Corporation |
Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
|
US7053080B2
(en)
*
|
2001-09-21 |
2006-05-30 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
|
NZ531060A
(en)
*
|
2001-09-21 |
2006-06-30 |
Schering Corp |
Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s)
|
US7056906B2
(en)
*
|
2001-09-21 |
2006-06-06 |
Schering Corporation |
Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
|
HRP20050163A2
(en)
|
2002-08-19 |
2005-06-30 |
Pfizer Products Inc. |
Combination therapy for hyperproliferative diseases
|
WO2004043457A1
(en)
*
|
2002-11-06 |
2004-05-27 |
Schering Corporation |
Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
|
MXPA05009502A
(es)
*
|
2003-03-07 |
2005-10-18 |
Schering Corp |
Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
|
US7459442B2
(en)
|
2003-03-07 |
2008-12-02 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
ATE406364T1
(de)
|
2003-03-07 |
2008-09-15 |
Schering Corp |
Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
|
MXPA05009501A
(es)
|
2003-03-07 |
2005-10-18 |
Schering Corp |
Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
|
US20050037063A1
(en)
*
|
2003-07-21 |
2005-02-17 |
Bolton Anthony E. |
Combined therapies
|
JP2007510659A
(ja)
*
|
2003-11-05 |
2007-04-26 |
シェーリング コーポレイション |
脂質調節剤および置換アゼチジノンの組み合わせならびに血管状態の処置
|
BRPI0507586A
(pt)
*
|
2004-02-10 |
2007-07-03 |
Hoffmann La Roche |
moduladores de receptor de quimiocina ccr5
|
US20060063803A1
(en)
*
|
2004-09-23 |
2006-03-23 |
Pfizer Inc |
4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
|
GT200600381A
(es)
|
2005-08-25 |
2007-03-28 |
|
Compuestos organicos
|
US7741317B2
(en)
|
2005-10-21 |
2010-06-22 |
Bristol-Myers Squibb Company |
LXR modulators
|
US7888376B2
(en)
|
2005-11-23 |
2011-02-15 |
Bristol-Myers Squibb Company |
Heterocyclic CETP inhibitors
|
US7919506B2
(en)
|
2006-03-10 |
2011-04-05 |
Pfizer Inc. |
Dibenzyl amine compounds and derivatives
|
US8383660B2
(en)
|
2006-03-10 |
2013-02-26 |
Pfizer Inc. |
Dibenzyl amine compounds and derivatives
|
US8404896B2
(en)
|
2006-12-01 |
2013-03-26 |
Bristol-Myers Squibb Company |
N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases
|
MX2009010503A
(es)
*
|
2007-03-29 |
2009-10-19 |
Hoffmann La Roche |
Compuestos heterociclicos antiviricos.
|
CN103601792B
(zh)
|
2007-06-04 |
2016-06-29 |
协同医药品公司 |
有效用于胃肠功能紊乱、炎症、癌症和其他疾病治疗的鸟苷酸环化酶激动剂
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
CA2726917C
(en)
|
2008-06-04 |
2018-06-26 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
EP2321341B1
(en)
|
2008-07-16 |
2017-02-22 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
CN102766147B
(zh)
*
|
2012-08-03 |
2015-07-15 |
无锡药兴医药科技有限公司 |
一种芬司匹利及其氢卤酸盐的制备方法
|
US9486494B2
(en)
|
2013-03-15 |
2016-11-08 |
Synergy Pharmaceuticals, Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
CA2905438A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
HK1213886A1
(zh)
|
2013-04-17 |
2016-07-15 |
辉瑞大药厂 |
用於治療心血管疾病的n-哌啶-3-基苯甲酰胺衍生物
|
SI3004138T1
(sl)
|
2013-06-05 |
2024-07-31 |
Bausch Health Ireland Limited |
Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo
|
GB201416346D0
(en)
*
|
2014-09-16 |
2014-10-29 |
Shire Internat Gmbh |
Spirocyclic derivatives
|
WO2016055901A1
(en)
|
2014-10-08 |
2016-04-14 |
Pfizer Inc. |
Substituted amide compounds
|
MX2021008533A
(es)
|
2019-01-18 |
2021-08-19 |
Astrazeneca Ab |
Inhibidores de la pcsk9 y metodos de uso de los mismos.
|